Search Results - "Knott, Aine"
-
1
Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma
Published in Clinical cancer research (01-01-2021)“…Dexamethasone, a uniquely potent corticosteroid, is frequently administered to patients with brain tumors to decrease tumor-associated edema, but limited data…”
Get full text
Journal Article -
2
ERK Inhibitor LY3214996-Based Treatment Strategies for RAS -Driven Lung Cancer
Published in Molecular cancer therapeutics (01-04-2021)“…gene mutations are the most frequent oncogenic event in lung cancer. They activate multiple RAS-centric signaling networks among them the MAPK, PI3K, and RB…”
Get full text
Journal Article -
3
Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM)
Published in British journal of cancer (17-08-2021)“…Background Malignant pleural mesothelioma (MPM) is a highly aggressive cancer with a dismal prognosis. There is increasing interest in targeting chromatin…”
Get full text
Journal Article -
4
Developing SHP2-based combination therapy for KRAS-amplified cancer
Published in JCI insight (08-02-2023)“…Gastroesophageal adenocarcinomas (GEAs) harbor recurrent amplification of KRAS, leading to marked overexpression of WT KRAS protein. We previously demonstrated…”
Get full text
Journal Article -
5
Milademetan is a highly potent MDM2 inhibitor in Merkel cell carcinoma
Published in JCI insight (08-07-2022)“…Merkel cell carcinoma (MCC) is an aggressive neuroendocrine carcinoma of the skin with 2 etiologies. Merkel cell polyomavirus (MCPyV) integration is present in…”
Get full text
Journal Article -
6
Abstract P203: Milademetan is a potent, murine double minute 2 (MDM2) inhibitor, highly active in TP53 wild-type (p53WT) Merkel cell carcinoma (MCC) cell lines
Published in Molecular cancer therapeutics (01-12-2021)“…Abstract Background: MCC is a highly aggressive neuroendocrine carcinoma of the skin with a poor overall prognosis. Current treatment options include surgery…”
Get full text
Journal Article -
7
Milademetan is a highly potent MDM2 inhibitor in TP53 wild-type (p53 WT) models of Merkel cell carcinoma (MCC)
Published in Journal of investigative dermatology (01-10-2022)Get full text
Journal Article -
8
Abstract C020: Unconvering the hidden immunosuppressive landscape in pancreatic ductal adenocarcinoma
Published in Cancer research (Chicago, Ill.) (16-01-2024)“…Abstract Pancreatic ductal adenocarcinoma (PDA) is one of the deadliest forms of cancer with an extremely low survival rate. Despite the success of therapeutic…”
Get full text
Journal Article -
9
IMMU-09. CONCURRENT DEXAMETHASONE LIMITS THE CLINICAL BENEFIT OF IMMUNE CHECKPOINT BLOCKADE IN GLIOBLASTOMA
Published in Neuro-oncology (Charlottesville, Va.) (09-11-2020)“…Abstract BACKGROUND Dexamethasone, a uniquely potent corticosteroid, is frequently administered to brain tumor patients to decrease tumor-associated edema, but…”
Get full text
Journal Article -
10
Abstract 6377: Developing combination therapy with SHP2 inhibition for CIN-type gastroesophageal adenocarcinoma with KRAS amplification
Published in Cancer research (Chicago, Ill.) (15-06-2022)“…Abstract Recent studies from the cancer genome atlas (TCGA. Nature. 2014) (TCGA. Nature. 2017) and other groups showed that a molecular subtype with…”
Get full text
Journal Article